141 related articles for article (PubMed ID: 18065490)
1. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
[TBL] [Abstract][Full Text] [Related]
3. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
4. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Zhang G; Park MA; Mitchell C; Hamed H; Rahmani M; Martin AP; Curiel DT; Yacoub A; Graf M; Lee R; Roberts JD; Fisher PB; Grant S; Dent P
Clin Cancer Res; 2008 Sep; 14(17):5385-99. PubMed ID: 18765530
[TBL] [Abstract][Full Text] [Related]
6. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
9. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
11. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
12. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
[TBL] [Abstract][Full Text] [Related]
13. Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
Huang JM; Sheard MA; Ji L; Sposto R; Keshelava N
Mol Cancer Ther; 2010 Dec; 9(12):3289-301. PubMed ID: 21159612
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Cartee L; Maggio SC; Smith R; Sankala HM; Dent P; Grant S
Mol Cancer Ther; 2003 Jan; 2(1):83-93. PubMed ID: 12533676
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
[TBL] [Abstract][Full Text] [Related]
18. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Ge Y; Byun JS; De Luca P; Gueron G; Yabe IM; Sadiq-Ali SG; Figg WD; Quintero J; Haggerty CM; Li QQ; De Siervi A; Gardner K
Mol Pharmacol; 2008 Sep; 74(3):872-83. PubMed ID: 18556456
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
